Publications by authors named "T PARTANEN"

Background: In the development of effective telerehabilitation (TR) interventions, understanding the various characteristics affecting its practice is essential. Remote connection creates a new technically shaped environment for therapy and, therefore, previous therapy methods do not work the same way as before.

Objective: The objective of this survey was to describe the practice of TR through the socio-technical theory approach.

View Article and Find Full Text PDF

Puumala hantavirus (PUUV), carried and spread by the bank vole (), causes a mild form of hemorrhagic fever with renal syndrome (HFRS) called nephropathia epidemica (NE). Acute high fever, acute kidney injury (AKI), thrombocytopenia, and hematuria are typical features of this syndrome. In addition, headache, blurred vision, insomnia, vertigo, and nausea are commonly associated with the disease.

View Article and Find Full Text PDF
Article Synopsis
  • Puumala hantavirus (PUUV) can lead to hemorrhagic fever with renal syndrome (HFRS) in Northern Europe, and while it typically has mild effects, it can occasionally cause serious complications like encephalitis.
  • This study investigated whether genetic defects in the TLR3 gene, similar to those seen in individuals with HSV-1 encephalitis, might contribute to PUUV-related encephalitis.
  • The researchers found a rare TLR3 variant in two of seven patients with PUUV encephalitis, indicating that mutations in this gene could play a role in the severity of such infections, warranting further research into other similar viral encephalitis cases.
View Article and Find Full Text PDF

Reports on real-world experience on efficacy of bezlotoxumab (BEZ) has been lacking thus far. We retrospectively studied the efficacy and safety of BEZ in preventing the recurrence of Clostridium difficile infection (CDI) in five university hospitals in Finland. Seventy-three percent of our 46 patients remained free of recurrence in the following 3 months and the performance remained as 71% effective also among immunocompromised patients.

View Article and Find Full Text PDF